middle.news
Bubs Opens a Bigger US Growth Platform With Permanent FDA Approval
9:39am on Thursday 10th of September, 2026 AEST
•
Consumer Staples
Read Story
Bubs Opens a Bigger US Growth Platform With Permanent FDA Approval
9:39am on Thursday 10th of September, 2026 AEST
Key Points
Permanent FDA authorisation for Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential
US generated AUD 66 million, or 59% of FY26 revenue
Bubs holds 24% of the US goat infant formula segment by value
Company assessing US contract manufacturing opportunities with a stated TAM above AUD 350 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bubs Australia (ASX:BUB)
OPEN ARTICLE